SURVYR

DXCM

DexCom, Inc.
$78.62
+$0.06 (0.08%)Oct 28 close
Health CareS&P 500 CompareTechnicals
1M3M6M1Y2Y
-23%-10%+4%+17%+31%Oct 2025Oct 2026Apr 202652w high $92.5952w low $54.11
DXCMSPY
Wall St. Highest PT $115.00 (+46.3%) Wall St. Avg PT $96.46 (+22.7%)
$55$71$87$103$118POC $72Hi $115Avg $96
Underwater Drawdown %Max DD -22.6%Current -14.9%
0.0%-22.6%
Relative Strength vs SPY-2.6% vs SPYUnderperforming
+32%0%-32%
1W
−$1.64 (2.04%)
1M
−$8.06 (9.30%)
3M
+$3.48 (4.63%)
6M
+$21.06 (36.59%)
YTD
+$12.25 (18.46%)
1Y
+$9.39 (13.56%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
26 analysts · mean score 1.34
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$78.62
Average target$96.46
+$17.84 (+22.7%) upsideaverage target vs current price
CurrentAverageMedian
Low$79.00
Median$96.46
High$115.00
12-month Wall Street target range
Recent analyst rating changes · 8
Reiterated
2026-10-12 · BTIG reiterated Buy on DXCM
Initiated
2026-10-07 · Barclays started covering DXCM at Overweight
Reiterated
2026-10-01 · RBC Capital reiterated Outperform on DXCM
Reiterated
2026-09-18 · Truist Securities reiterated Buy on DXCM
Reiterated
2026-09-18 · TD Cowen reiterated Buy on DXCM
Reiterated
2026-08-04 · Argus Research reiterated Buy on DXCM
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$30.3B
P/E (last 12 months)31.8
P/E (next 12 months, estimated)25.7
52-week range$54.11 – $92.59
Revenue growth (latest quarter vs a year ago)+13.1%
Dividend yieldNo dividend
Analyst consensusStrong Buy (26)
Average analyst price target$96.46 (+23%)

What they do

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system. It markets its products directly to endocrinologists, physicians, and diabetes educators.

Healthcare · Medical Devices
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum
78th percentile in sector
B+
12-1 return: +48.2%
Percentile within its GICS sector across the S&P 1500.
Growth
69th percentile in sector
B
Revenue growth (YoY): +13.1%
Percentile within its GICS sector across the S&P 1500.
Value
22nd percentile in sector
D
Forward E/P: 3.6% · EBITDA/EV: 4.4%
Percentile within its GICS sector across the S&P 1500.
Profitability
86th percentile in sector
A-
Profit margin: +20.1% · Return on equity: +38.5%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
ranked 115 of 499 · 12-month momentum 35.3%
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

DXCM earningsReports tomorrow
Next report · quarter Sep 2026
Thu Oct 29, 2026After the close
EPS consensus$0.67 range $0.63–$0.72
Revenue consensus$1.3B 25 analysts
Last 4 quarters · EPS vs estimate
Jul 30, 2026$0.70est $0.61+15.1%Above estimates
Apr 30, 2026$0.56est $0.47+19.0%Above estimates
Feb 12, 2026$0.68est $0.65+4.5%Above estimates
Oct 30, 2025$0.61est $0.57+7.5%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-21 18:28:51 ET
24-1025-0225-0525-0725-1026-0226-0426-070.000.70
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$1.3B+13.1%
2026-03-31$1.2B–
2025-12-31$1.3B–
2025-09-30$1.2B–
2025-06-30$1.2B–

News & catalysts

More news
Abbott (ABT): Can Libre Keep Growing as Glucose Monitoring Becomes More Competitive?
Insider Monkey · Oct 20
DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study
Zacks · Oct 20
Global Wearable Electronics Market Report 2026-2036 | AI, Extended Reality, and Digital Health Drive New Growth and Investment Opportunities
GlobeNewswire · Oct 19
Vaso Stock Surges 149% in a Year: What's Behind the Rally?
Zacks · Oct 16
NEJM study supports CGM use for people with diabetes who don’t take insulin
MedTech Dive · Oct 15
Rating changes
Reiterated
2026-10-12 · BTIG reiterated Buy on DXCM
Initiated
2026-10-07 · Barclays started covering DXCM at Overweight
Reiterated
2026-10-01 · RBC Capital reiterated Outperform on DXCM
Reiterated
2026-09-18 · Truist Securities reiterated Buy on DXCM
Reiterated
2026-09-18 · TD Cowen reiterated Buy on DXCM
Reiterated
2026-08-04 · Argus Research reiterated Buy on DXCM

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Brown Michael Jon
EVP Chief Legal Compliance Off · 2026-10-15
Sell
$145.3K
Stern Sadie
EVP Chief People & Culture Off · 2026-09-28
Sell
$221.0K
Brown Michael Jon
EVP Chief Legal Compliance Off · 2026-09-15
Sell
$142.9K
Augustinos Nicholas
Director · 2026-09-15
Sell
$549.5K
Augustinos Nicholas
Director · 2026-09-14
Sell
$130.2K
Sylvain Jereme M
EVP, Chief Financal Officer · 2026-09-10
Sell
$302.9K
Stern Sadie
EVP Chief People & Culture Off · 2026-08-27
Sell
$226.7K
Sayer Kevin R
Director, Executive Chair · 2026-08-20
Sell
$8.9K
Sayer Kevin R
Director, Executive Chair · 2026-08-20
Sell
$667.3K
Sayer Kevin R
Director, Executive Chair · 2026-08-20
Sell
$1.7M
Brown Michael Jon
EVP Chief Legal Compliance Off · 2026-08-14
Sell
$156.3K
Heller Bridgette P
Director · 2026-08-12
Sell
$89.3K

Stats refreshed 2026-10-21 18:28:51 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026